{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:30:18Z","timestamp":1754159418611,"version":"3.41.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10620-025-08947-7","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T08:16:47Z","timestamp":1743754607000},"page":"2297-2301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute Severe Ulcerative Colitis in the Modern Era Spotlight on Opioids, Small Molecule Therapy, and Interdisciplinary Communication"],"prefix":"10.1007","volume":"70","author":[{"given":"Catalina","family":"Mulanax","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando S.","family":"Velayos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"8947_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","volume":"9","author":"P Riviere","year":"2024","unstructured":"Riviere P, Li Wai Suen C, Chaparro M et al. Acute severe ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol Hepatol. 2024;9:251\u2013262. https:\/\/doi.org\/10.1016\/S2468-1253(23)00313-8.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"8947_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/apt.12473","volume":"38","author":"RW Lynch","year":"2013","unstructured":"Lynch RW, Lowe D, Protheroe A et al. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther. 2013;38:935\u2013945. https:\/\/doi.org\/10.1111\/apt.12473.","journal-title":"Aliment Pharmacol Ther."},{"key":"8947_CR3","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","volume":"330","author":"S Lichtiger","year":"1994","unstructured":"Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841\u20131845. https:\/\/doi.org\/10.1056\/NEJM199406303302601.","journal-title":"N Engl J Med."},{"key":"8947_CR4","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","volume":"128","author":"G Jarnerot","year":"2005","unstructured":"Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805\u20131811. https:\/\/doi.org\/10.1053\/j.gastro.2005.03.003.","journal-title":"Gastroenterology."},{"key":"8947_CR5","doi-asserted-by":"publisher","unstructured":"Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350\u20135 e2. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.016","DOI":"10.1053\/j.gastro.2015.04.016"},{"key":"8947_CR6","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1097\/j.pain.0000000000002304","volume":"162","author":"N Bakshi","year":"2021","unstructured":"Bakshi N, Hart AL, Lee MC et al. Chronic pain in patients with inflammatory bowel disease. Pain. 2021;162:2466\u20132471. https:\/\/doi.org\/10.1097\/j.pain.0000000000002304.","journal-title":"Pain."},{"key":"8947_CR7","doi-asserted-by":"publisher","first-page":"22396","DOI":"10.1038\/s41598-023-48126-0","volume":"13","author":"SK Berry","year":"2023","unstructured":"Berry SK, Takakura W, Patel D et al. A randomized controlled trial of a proactive analgesic protocol demonstrates reduced opioid use among hospitalized adults with inflammatory bowel disease. Sci Rep. 2023;13:22396. https:\/\/doi.org\/10.1038\/s41598-023-48126-0.","journal-title":"Sci Rep."},{"key":"8947_CR8","doi-asserted-by":"publisher","unstructured":"Grunkemeier DM, Cassara JE, Dalton CB, et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007;5(10):1126\u201339; quiz 1121\u20132. https:\/\/doi.org\/10.1016\/j.cgh.2007.06.013","DOI":"10.1016\/j.cgh.2007.06.013"},{"key":"8947_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u20131736. https:\/\/doi.org\/10.1056\/NEJMoa1606910.","journal-title":"N Engl J Med."},{"key":"8947_CR10","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5.","journal-title":"Lancet."},{"key":"8947_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41575-022-00722-7","volume":"20","author":"S Danese","year":"2023","unstructured":"Danese S, Solitano V, Jairath V, Peyrin-Biroulet L. Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance. Nat Rev Gastroenterol Hepatol. 2023;20:129\u2013130. https:\/\/doi.org\/10.1038\/s41575-022-00722-7.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"8947_CR12","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","volume":"19","author":"JA Berinstein","year":"2021","unstructured":"Berinstein JA, Sheehan JL, Dias M et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol. 2021;19:2112-2120e1. https:\/\/doi.org\/10.1016\/j.cgh.2021.05.038.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8947_CR13","doi-asserted-by":"publisher","unstructured":"Berinstein JA, Karl T, Patel A, et al. Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience. Am J Gastroenterol. 2024. https:\/\/doi.org\/10.14309\/ajg.0000000000002674","DOI":"10.14309\/ajg.0000000000002674"},{"key":"8947_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08792-0","author":"K Fansiwala","year":"2024","unstructured":"Fansiwala K, Sauk JS. Small molecules, big results: how jak inhibitors have transformed the treatment of patients with IBD. Dig Dis Sci. 2024. https:\/\/doi.org\/10.1007\/s10620-024-08792-0.","journal-title":"Dig Dis Sci."},{"key":"8947_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","volume":"65","author":"AJ Yarur","year":"2016","unstructured":"Yarur AJ, Jain A, Sussman DA et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65:249\u2013255. https:\/\/doi.org\/10.1136\/gutjnl-2014-308099.","journal-title":"Gut."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-08947-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:32:07Z","timestamp":1753435927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-08947-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["8947"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-08947-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}